Guideline on allergen-specific immunotherapy in IgE-mediated allergic diseases
详细信息    查看全文
  • 作者：Prof. Dr. Oliver Pfaar (1) (2) (30)
    Claus Bachert (3)
    Albrecht Bufe (4)
    Roland Buhl (5)
    Christof Ebner (6)
    Peter Eng (7)
    Frank Friedrichs (8)
    Thomas Fuchs (9)
    Eckard Hamelmann (10)
    Doris Hartwig-Bade (11)
    Thomas Hering (12)
    Isidor Huttegger (13)
    Kirsten Jung (14)
    Ludger Klimek (1)
    Matthias Volkmar Kopp (15)
    Hans Merk (16)
    Uta Rabe (17)
    Joachim Saloga (18)
    Peter Schmid-Grendelmeier (19)
    Antje Schuster (20)
    Nicolaus Schwerk (21)
    Helmut Sitter (22)
    Ulrich Umpfenbach (23)
    Bettina Wedi (24)
    Stefan W枚hrl (25)
    Margitta Worm (26)
    J枚rg Kleine-Tebbe (27)
    Susanne Kaul (28)
    Anja Schwalfenberg (29)

    1. Center for Rhinology and Allergology     ; Wiesbaden ; Germany
    2. Department of Otorhinolaryngology     ; Head and Neck Surgery ; University Hospital Mannheim ; Mannheim ; Germany
    30. Center for Rhinology and Allergology Wiesbaden     ; Department of Otorhinolaryngology ; Head and Neck Surgery ; University Hospital Mannheim ; An den Quellen 10 ; 65189 ; Wiesbaden ; Germany
    3. Department of Otorhinolaryngology     ; Ghent University Hospital ; Ghent ; Belgium
    4. Department of Experimental Pneumology     ; Ruhr-University Bochum ; Bochum ; Germany
    5. Pulmonary Department     ; University Medical Center ; Johannes Gutenberg-University ; Mainz ; Germany
    6. Outpatient Clinic for Allergy and Clinical Immunology     ; Vienna ; Austria
    7. Department of Children and Adolescent Medicine     ; Aarau and Children鈥榮 Hospital Lucerne ; Lucerne ; Switzerland
    8. Pediatric and Adolescent Medicine Practice     ; Laurensberg ; Germany
    9. Department of Dermatology     ; Venereology and Allergology ; University Medical Center G枚ttingen ; Georg-August-University ; G枚ttingen ; Germany
    10. Department of Pediatric and Adolescent Medicine     ; Pediatric Center Bethel ; Evangelical Hospital ; Bielefeld ; Germany
    11. ENT Practice     ; L眉beck ; Germany
    12. Pulmonary Outpatient Practice     ; Tegel ; Berlin ; Germany
    13. Department of Pediatric and Adolescent Medicine     ; Paracelsus Private Medical University ; Salzburg Regional Hospitals ; Salzburg ; Austria
    14. Dermatology Practice     ; Erfurt ; Germany
    15. Clinic of Pediatric and Adolescent Medicine     ; L眉beck University ; Airway Research Center North (ARCN) ; Member of the German Lung Center (DZL) ; L眉beck ; Germany
    16. Department of Dermatology and Allergology     ; University Hospital ; RWTH Aachen University ; Aachen ; Germany
    17. Department of Allergology     ; Johanniter-Krankenhaus im Fl盲ming Treuenbrietzen GmbH ; Treuenbrietzen Germany ; Treuenbrietzen ; Germany
    18. Department of Dermatology     ; University Medical Center ; Johannes-Gutenberg University ; Mainz ; Germany
    19. Allergy Unit     ; Department of Dermatology ; University Hospital of Zurich ; Zurich ; Switzerland
    20. Center for Pediatric and Adolescent Medicine     ; University Medical Center ; D眉sseldorf ; Germany
    21. University Children鈥檚 hospital     ; Department of Pediatric Pneumology ; Allergology and Neonatology ; Hanover Medical University ; Hannover ; Germany
    22. Institute for Theoretical Surgery     ; Marburg University ; Marburg ; Germany
    23. Pediatric and Adolescent Medicine Practice     ; Viersen ; Germany
    24. Department of Dermatology     ; Allergology and Venereology ; Hannover Medical University ; Hannover ; Germany
    25. Floridsdorf Allergy Center     ; Vienna ; Austria
    26. Allergy-Centre-Charit茅     ; Department of Dermatology ; Venereology ; and Allergology ; Charit茅 University Hospital ; Berlin ; Germany
    27. Allergy and Asthma Center Westend     ; Berlin ; Germany
    28. Division of Allergology     ; Paul-Ehrlich-Institut ; Federal Institute for Vaccines and Biomedicines ; Langen ; Germany
    29. German Allergy and Asthma Association     ; M枚nchengladbach ; Germany
  • 关键词：allergen ; specific immunotherapy ; AIT ; Hyposensitization ; guideline ; allergen ; allergen extract ; allergic disease ; allergic rhinitis ; allergic asthma
  • 刊名：Allergo Journal
  • 出版年：2014
  • 出版时间：December 2014
  • 年：2014
  • 卷：23
  • 期：8
  • 页码：282-319
  • 全文大小：1,144 KB
  • 参考文献：1. Kleine-Tebbe J, Bufe A, Ebner C et al. [Specific immunotherapy (hyposensitization) for IgE-mediated allergic diseases. Guideline of the German Society of Allergy and Clinical Immunology (DGAKI), of the Association of German Allergists (脛DA) and the Society of Pediatric Allergy and Environmental Medicine (GPA), of the Austrian Society of Allergy and Immunology (脰GAI) and the Swiss Society of Allergy and Immunology]. Allergo J 2009;18:509鈥?7
    2. Bagnasco M, Altrinetti V, Pesce G et al. Pharmacokinetics of Der p 2 allergen and derived monomeric allergoid in allergic volunteers. Int Arch Allergy Immunol 2005;138:197鈥?02
    3. Martinez-G贸mez JM, Johansen P, Erdmann I, Senti G, Crameri R, K眉ndig TM. Intralymphatic injections as a new administration route for allergen-specific immunotherapy. Int Arch Allergy Immunol 2009;150:59鈥?5
    4. Allam JP, W眉rtzen PA, Reinartz M et al. Phl p 5 resorption in human oral mucosa leads to dose-dependent and time-dependent allergen binding by oral mucosal Langerhans cells, attenuates their maturation, and enhances their migratory and TGF-beta1 and IL-10-producing properties. J Allergy Clin Immunol 2010;126:638鈥?5.e1
    5. Akdis M, Akdis CA. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol 2007;119:780鈥?1
    6. Nouri-Aria KT, Wachholz PA, Francis JN et al. Grass pollen immunotherapy induces mucosal and peripheral IL-10 responses and blocking IgG activity. J Immunol 2004;172:3252鈥?
    7. Takhar P, Smurthwaite L, Coker HA et al. Allergen drives class switching to IgE in the nasal mucosa in allergic rhinitis. J Immunol 2005;174:5024鈥?2
    8. Reisinger J, Horak F, Pauli G et al. Allergen-specific nasal IgG antibodies induced by vaccination with genetically modified allergens are associated with reduced nasal allergen sensitivity. J Allergy Clin Immunol 2005;116:347鈥?4
    9. Akdis M, Verhagen J, Taylor A et al. Immune responses in healthy and allergic individuals are characterized by a fine balance between allergen-specific T regulatory 1 and T helper 2 cells. J Exp Med 2004;199:1567鈥?5
    10. Li JT, Lockey RF, Bernstein I, Portnoy JM, Nicklas RA. Allergen immunotherapy: a practice parameter. American Academy of Allergy, Asthma and Immunology. American College of Allergy, Asthma and Immunology. Ann Allergy Asthma Immunol 2003;90(1 Suppl 1):1鈥?0
    11. European Medicines Agency; Committee for medicinal products for human use (CHMP). Guideline on allergen products: production and quality issues. EMEA/CHMP/BWP/304831/2007. London, 20 November, 2008
    12. Ree R van, Chapman MD, Ferreira F et al. The CREATE project: development of certified reference materials for allergenic products and validation of methods for their quantification. Allergy 2008;63:310鈥?6
    13. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, eds. Monograph: Allergen Products - Producta Allergenica 07/2014:1063. as implemented of 01.07.2014. Strasbourg: Council of Europe; 2014:p. 3945-47
    14. Grammer LC, Shaughnessy MA, Patterson R. Modified forms of allergen immunotherapy. J Allergy Clin Immunol 1985;76:397鈥?01
    15. Pfaar O, Kleine-Tebbe J, H枚rmann K, Klimek L. Allergen-specific immunotherapy: which outcome measures are useful in monitoring clinical trials? Immunol Allergy Clin North Am 2011;31:289鈥?09
    16. Calderon MA, Eichel A, Makatsori M, Pfaar O. Comparability of subcutaneous and sublingual immunotherapy outcomes in allergic rhinitis clinical trials. Curr Opin Allergy Clin Immunol 2012;12:249鈥?6
    17. Pfaar O, Demoly P, Gerth van Wijk R et al. Recommendations for the standardization of clinical outcomes used in allergen immunotherapy trials for allergic rhinoconjunctivitis: an EAACI Position Paper. Allergy 2014;69:854鈥?7
    18. Grouin JM, Vicaut E, Jean-Alphonse S et al. The average adjusted symptom score, a new primary efficacy end-point for specific allergen immunotherapy trials. Clin Exp Allergy 2011;41:1282鈥?
    19. Didier A, Melac M, Montagut A, Lheritier-Barrand M, Tabar A, Worm M. Agreement of efficacy assessments for five-grass pollen sublingual tablet immunotherapy. Allergy 2009;64:166鈥?1
    20. Clark J, Schall R. Assessment of combined symptom and medication scores for rhinoconjunctivitis immunotherapy clinical trials. Allergy 2007;62:1023鈥?
    21. European Medicines Agency; Commitee for medicinal products for human use (CHMP), eds. Guideline on the clinical development of products for specific immunotherapy for the treatment of allergic diseases. CHMP/EWP/18504/2006. London, 20. November 2008
    22. Bousquet J, Sch眉nemann HJ, Bousquet PJ et al. How to design and evaluate randomized controlled trials in immunotherapy for allergic rhinitis: an ARIA-GA(2)LEN statement. Allergy 2011;66:765鈥?4
    23. Bousquet PJ, Brozek J, Bachert C et al. The CONSORT statement checklist in allergen-specific immunotherapy: a GA2LEN paper. Allergy 2009;64:1737鈥?5
    24. Brehler R, Klimek L, Kopp MV, Christian Virchow J. Specific immunotherapy-indications and mode of action. Dtsch Arztebl Int 2013;110:148鈥?8
    25. Verordnung 眉ber die Ausdehnung der Vorschriften 眉ber die Zulassung der Arzneimittel auf Therapieallergene, die f眉r einzelne Personen auf Grund einer Rezeptur hergestellt werden, sowie 眉ber Verfahrensregelungen der staatlichen Chargenpr眉fung (Therapieallergene-Verordnung). Bundesgesetzbl 2008;51:2177-8
    26. Englert S, May S, Kaul S, Vieths S. [The therapy allergens ordinance (鈥淭herapieallergene-Verordnung鈥? - Background and effects]. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2012; 55:351鈥?7
    27. Kaul S, Jappe U, Vieths S, May S. [Surveillance of allergen extracts for specific immunotherapy: legal regulations and procedures]. Allergo J 2008;17:385鈥?3
    28. May S, Haustein D. [Named patient products in specific immunotherapy. Necessities and sources of error]. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2001;44:719鈥?3
    29. Incorvaia C, Agostinis F, Amoroso S et al. Pharmacoeconomics of subcutaneous allergen immunotherapy. Eur Ann Allergy Clin Immunol 2007;39 Spec No:17鈥?0
    30. Incorvaia C, Mauro M, Ridolo E et al. Patient鈥檚 compliance with allergen immunotherapy. Patient Prefer Adherence 2008;2:247鈥?1
    31. Bocking C, Renz H, Pfefferle PI. Prevalence and socio-economic relevance of allergies in Germany. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2012;55:303鈥?
    32. Lamb CE, Ratner PH, Johnson CE et al. Economic impact of workplace productivity losses due to allergic rhinitis compared with select medical conditions in the United States from an employer perspective. Curr Med Res Opin 2006;22:1203鈥?0
    33. Shaaban R, Zureik M, Soussan D et al. Rhinitis and onset of asthma: a longitudinal population-based study. Lancet 2008;372:1049鈥?7
    34. Jacobsen L, Niggemann B, Dreborg S et al. Specific immunotherapy has long-term preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy 2007;62:943鈥?
    35. Hagen A, Gorenoi V, Schonermark MP. Specific immunotherapy (SIT) in the treatment of allergic rhinitis. GMS Health Technol Assess 2010;6:Doc01 doi: 10.3205/hta000079
    36. Ronaldson S, Taylor M, Bech PG, Shenton R, Bufe A. Economic evaluation of SQ-standardized grass allergy immunotherapy tablet (Grazax(庐)) in children. Clinicoecon Outcomes Res 2014;6:187鈥?6
    37. Br眉ggenj眉rgen B, Reinhold T, Brehler R et al. Cost-effectiveness of specific subcutaneous immunotherapy in patients with allergic rhinitis and allergic asthma. Ann Allergy Asthma Immunol 2008;101:316鈥?4
    38. Westerhout KY, Verheggen BG, Schreder CH, Augustin M. Cost effectiveness analysis of immunotherapy in patients with grass pollen allergic rhinoconjunctivitis in Germany. J Med Econ 2012;15:906鈥?7
    39. Sch盲dlich PK and Brecht JG. Economic evaluation of specific immunotherapy versus symptomatic treatment of allergic rhinitis in Germany. Pharmacoeconomics 2000; 17: 37鈥?2
    40. Bachert C. Comparison of solutions for sublingual immunotherapy. Int Arch Allergy Immunol 2007;142:89鈥?0
    41. Calderon MA, Casale TB, Togias A, Bousquet J, Durham SR, Demoly P. Allergen-specific immunotherapy for respiratory allergies: from meta-analysis to registration and beyond. J Allergy Clin Immunol 2011;127:30鈥?
    42. Compalati E, Penagos M, Tarantini F, Passalacqua G, Canonica GW. Specific immunotherapy for respiratory allergy: state of the art according to current meta-analyses. Ann Allergy Asthma Immunol 2009;102:22鈥?
    43. Calderon M, M枚sges R, Hellmich M, Demoly P. Towards evidence-based medicine in specific grass pollen immunotherapy. Allergy 2010;65:420鈥?4
    44. Dretzke J, Meadows A, Novielli N, Huissoon A, Fry-Smith A, Meads C. Subcutaneous and sublingual immunotherapy for seasonal allergic rhinitis: a systematic review and indirect comparison. J Allergy Clin Immunol 2013;131:1361鈥?
    45. Calderon MA, Casale TB, Nelson HS, Demoly P. An evidence-based analysis of house dust mite allergen immunotherapy: a call for more rigorous clinical studies. J Allergy Clin Immunol 2013;132:1322鈥?6
    46. Canonica GW, Baena-Cagnani CE, Bousquet J et al. Recommendations for standardization of clinical trials with allergen specific immunotherapy for respiratory allergy. A statement of a World Allergy Organization (WAO) taskforce. Allergy 2007;62:317鈥?4
    47. Carr W, Bernstein J, Lieberman P et al. A novel intranasal therapy of azelastine with fluticasone for the treatment of allergic rhinitis. J Allergy Clin Immunol 2012;129:1282鈥?.e10
    48. Calderon MA, Alves B, Jacobson M, Hurwitz B, Sheikh A, Durham S. Allergen injection immunotherapy for seasonal allergic rhinitis. Cochrane Database Syst Rev 2007;1:CD001936
    49. Matricardi PM, Kuna P, Panetta V, Wahn U, Narkus A. Subcutaneous immunotherapy and pharmacotherapy in seasonal allergic rhinitis: a comparison based on meta-analyses. J Allergy Clin Immunol 2011;128:791鈥?.e6
    50. Kuna P, Kaczmarek J, Kupczyk M. Efficacy and safety of immunotherapy for allergies to Alternaria alternata in children. J Allergy Clin Immunol 2011;127:502鈥?.e1-6
    51. Bergmann KC. [Specific immunotherapy in allergic asthma]. Pneumologie 2003;57:84鈥?0
    52. Bousquet J, Lockey RF, Malling HJ. Allergen immunotherapy: therapeutic vaccines for allergic diseases. WHO Position paper. Allergy 1998;53(44 Suppl):1鈥?2
    53. Buhl R, Berdel D, Cri茅e CP et al. [Guidelines for diagnosis and treatment of asthma patients]. Pneumologie 2006;60:139鈥?3
    54. Gillissen A, Bergmann KC, Kleine-Tebbe J et al. [Specific immunotherapy in allergic asthma]. Dtsch Med Wochenschr 2003;128:204鈥?
    55. Global Initiative for Asthma (GINA), ed. Global strategy for asthma management and prevention (updated 2005). www.ginasthma.org
    56. Global Initiative for Asthma (GINA), ed. Global strategy for asthma management and prevention (updated 2007). www.ginasthma.org
    57. Walker SM, Durham SR, Till SJ et al. Immunotherapy for allergic rhinitis. Clin Exp Allergy 2011;41:1177鈥?00
    58. Bousquet J. Specific immunotherapy in asthma. Allergy 1999;54 Suppl 56:37鈥?
    59. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev 2010;8:CD001186
    60. Amin HS, Liss GM, Bernstein DI. Evaluation of near-fatal reactions to allergen immunotherapy injections. J Allergy Clin Immunol 2006;117:169鈥?5
    61. Zielen S, Kardos P, Madonini E. Steroid-sparing effects with allergen-specific immunotherapy in children with asthma: a randomized controlled trial. J Allergy Clin Immunol 2010;126:942鈥?
    62. Frew AJ, Powell RJ, Corrigan CJ, Durham SR. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:319鈥?5
    63. Corrigan CJ, Kettner J, Doemer C, Cromwell O, Narkus A. Efficacy and safety of preseasonal-specific immunotherapy with an aluminium-adsorbed six-grass pollen allergoid. Allergy 2005;60:801鈥?
    64. Pfaar O, Urry Z, Robinson DS et al. A randomized placebo-controlled trial of rush preseasonal depigmented polymerized grass pollen immunotherapy. Allergy 2012;67:272鈥?
    65. Dubuske L, Frew A, Horak F et al. Ultrashort-specific immunotherapy successfully treats seasonal allergic rhinoconjunctivitis to grass pollen. Allergy Asthma Proc 2011;32:239鈥?7
    66. Brewczynski P, Kroon A. [Efficacy and safety of immunotherapy with modified grasspollen allergens. Results of a placebo-controlled study]. Allergologie 1999;22:411鈥?0
    67. Roberts G, Hurley C, Turcanu V, Lack G. Grass pollen immunotherapy as an effective therapy for childhood seasonal allergic asthma. J Allergy Clin Immunol 2006;117:263鈥?
    68. Arvidsson MB, L枚whagen O, Rak S. Effect of 2-year placebo-controlled immunotherapy on airway symptoms and medication in patients with birch pollen allergy. J Allergy Clin Immunol 2002;109:777鈥?3
    69. Balda BR, Wolf H, Baumgarten C et al. Tree-pollen allergy is efficiently treated by short-term immunotherapy (STI) with seven preseasonal injections of molecular standardized allergens. Allergy 1998;53:740鈥?
    70. B脴dtger U, Poulsen LK, Jacobi HH, Malling HJ. The safety and efficacy of subcutaneous birch pollen immunotherapy - a one-year, randomised, double-blind, placebo-controlled study. Allergy 2002;57:297鈥?05
    71. Neerven RJ van, Arvidsson M, Ipsen H, Sparholt SH, Rak S, W眉rtzen PA. A double-blind, placebo-controlled birch allergy vaccination study: inhibition of CD23-mediated serum-immunoglobulin E-facilitated allergen presentation. Clin Exp Allergy 2004;34:420鈥?
    72. Hoiby AS, Strand V, Robinson DS, Sager A, Rak S. Efficacy, safety, and immunological effects of a 2-year immunotherapy with Depigoid birch pollen extract: a randomized, double-blind, placebo-controlled study. Clin Exp Allergy 2010;40:1062鈥?0
    73. Pfaar O, Robinson DS, Sager A, Emuzyte R. Immunotherapy with depigmented-polymerized mixed tree pollen extract: a clinical trial and responder analysis. Allergy 2010;65:1614鈥?1
    74. Drachenberg KJ, Heinzkill M, Urban E. [Short-term immunotherapy with tree pollen allergoids and the adjuvant monophosphoryl lipid-A - results from a multicentre, placebo-controlled, randomised, double-blind study]. Allergologie 2002;25:466鈥?4
    75. Ameal A, Vega-Chicote JM, Fern谩ndez S et al. Double-blind and placebo-controlled study to assess efficacy and safety of a modified allergen extract of Dermatophagoides pteronyssinus in allergic asthma. Allergy 2005;60:1178鈥?3
    76. Pichler CE, Marquardsen A, Sparholt S et al. Specific immunotherapy with Dermatophagoides pteronyssinus and D. farinae results in decreased bronchial hyperreactivity. Allergy 1997;52:274鈥?3
    77. Riechelmann H, Schmutzhard J, Werf JF van der, Distler A, Kleinjans HA. Efficacy and safety of a glutaraldehyde-modified house dust mite extract in allergic rhinitis. Am J Rhinol Allergy 2010;24:e104鈥?
    78. Varney VA, Tabbah K, Mavroleon G, Frew AJ. Usefulness of specific immunotherapy in patients with severe perennial allergic rhinitis induced by house dust mite: a double-blind, randomized, placebo-controlled trial. Clin Exp Allergy 2003;33:1076鈥?2
    79. Blainey AD, Phillips MJ, Ollier S, Davies RJ. Hyposensitization with a tyrosine adsorbed extract of Dermatophagoides pteronyssinus in adults with perennial rhinitis. A controlled clinical trial. Allergy 1984;39:521鈥?
    80. Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebo-controlled, double-blind, double-dummy study. Int Arch Allergy Immunol 2012;157:288鈥?8
    81. Olsen OT, Larsen KR, Jacobsan L, Svendsen UG. A 1-year, placebo-controlled, double-blind house-dust-mite immunotherapy study in asthmatic adults. Allergy 1997; 52: 853鈥?
    82. Wang H, Lin X, Hao C et al. A double-blind, placebo-controlled study of house dust mite immunotherapy in Chinese asthmatic patients. Allergy 2006;61:191鈥?
    83. Garcia-Robaina JC, Sanchez I, Torre F de la, Fernandez-Caldas E, Casanovas M. Successful management of mite-allergic asthma with modified extracts of Dermatophagoides pteronyssinus and Dermatophagoides farinae in a double-blind, placebo-controlled study. J Allergy Clin Immunol 2006;118:1026鈥?2
    84. Blumberga G, Groes L, Haugaard L, Dahl R. Steroid-sparing effect of subcutaneous SQ-standardised specific immunotherapy in moderate and severe house dust mite allergic asthmatics. Allergy 2006;61:843鈥?
    85. Bucur J, Dreborg S, Einarsson R. Immunotherapy with dog and cat allergen preparations in dog-sensitive and cat-sensitive asthmatics. Ann Allergy 1989;62:355鈥?1
    86. Hedlin G, Graff-Lonnevig V, Heilborn H et al. Immunotherapy with cat- and dog-dander extracts. V. Effects of 3 years of treatment. J Allergy Clin Immunol 1991;87:955鈥?4
    87. Hedlin G, Heilborn H, Lilja G et al. Long-term follow-up of patients treated with a three-year course of cat or dog immunotherapy. J Allergy Clin Immunol 1995;96: 879鈥?5
    88. Nanda A, O鈥機onnor M, Anand M et al. Dose dependence and time course of the immunologic response to administration of standardized cat allergen extract. J Allergy Clin Immunol 2004;114:1339鈥?4
    89. Sundin B, Lilja G, Graff-Lonnevig V et al. Immunotherapy with partially purified and standardized animal dander extracts. I. Clinical results from a double-blind study on patients with animal dander asthma. J Allergy Clin Immunol 1986;77:478鈥?7
    90. Dreborg S, Agrell B, Foucard T, Kjellman NI, Koivikko A, Nilsson S. A double-blind, multicenter immunotherapy trial in children, using a purified and standardized Cladosporium herbarum preparation. I. Clinical results. Allergy 1986;41:131鈥?0
    91. Horst M, Hejjaoui A, Horst V, Michel FB, Bousquet J. Double-blind, placebo-controlled rush immunotherapy with a standardized Alternaria extract. J Allergy Clin Immunol 1990;85:460鈥?2
    92. Malling HJ, Dreborg S, Weeke B. Diagnosis and immunotherapy of mould allergy. V. Clinical efficacy and side effects of immunotherapy with Cladosporium herbarum. Allergy 1986;41:507鈥?9
    93. Mari A, Ballmer-Weber BK, Vieths S. The oral allergy syndrome: improved diagnostic and treatment methods. Curr Opin Allergy Clin Immunol 2005;5:267鈥?3
    94. Mauro M, Russello M, Incorvaia C et al. Birch-apple syndrome treated with birch pollen immunotherapy. Int Arch Allergy Immunol 2011;156:416鈥?2
    95. Bussmann C, B枚ckenhoff A, Henke H, Werfel T, Novak N. Does allergen-specific immunotherapy represent a therapeutic option for patients with atopic dermatitis? J Allergy Clin Immunol 2006;118:1292鈥?
    96. Novak N. Allergen specific immunotherapy for atopic dermatitis. Curr Opin Allergy Clin Immunol 2007;7:542鈥?6
    97. Werfel T, Breuer K, Rueff F et al. Usefulness of specific immunotherapy in patients with atopic dermatitis and allergic sensitization to house dust mites: a multi-centre, randomized, dose-response study. Allergy 2006;61:202鈥?
    98. Novak N, Bieber T, Hoffmann M et al. Efficacy and safety of subcutaneous allergen-specific immunotherapy with depigmented polymerized mite extract in atopic dermatitis. J Allergy Clin Immunol 2012;130:925鈥?1.e4
    99. Bae JM, Choi YY, Park CO, Chung KY, Lee KH. Efficacy of allergen-specific immunotherapy for atopic dermatitis: a systematic review and meta-analysis of randomized controlled trials. J Allergy Clin Immunol 2013;132:110鈥?
    100. Dahl R, Stender A, Rak S. Specific immunotherapy with SQ standardized grass allergen tablets in asthmatics with rhinoconjunctivitis. Allergy 2006;61:185鈥?0
    101. Dahl R, Kapp A, Colombo G et al. Efficacy and safety of sublingual immunotherapy with grass allergen tablets for seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;118:434鈥?0
    102. Didier A, Malling HJ, Worm M et al. Optimal dose, efficacy, and safety of once-daily sublingual immunotherapy with a 5-grass pollen tablet for seasonal allergic rhinitis. J Allergy Clin Immunol 2007;120:1338鈥?5
    103. Worm M. Efficacy and tolerability of high dose sublingual immunotherapy in patients with rhinoconjunctivitis. Allerg Immunol (Paris) 2006;38:355鈥?0
    104. Durham SR, Yang WH, Pedersen MR, Johansen N, Rak S. Sublingual immunotherapy with once-daily grass allergen tablets: a randomized controlled trial in seasonal allergic rhinoconjunctivitis. J Allergy Clin Immunol 2006;117:802鈥?
    105. Worm M, Rak S, Blay F de et al. Sustained efficacy and safety of a 300IR daily dose of a sublingual solution of birch pollen allergen extract in adults with allergic rhinoconjunctivitis: results of a double-blind, placebo-controlled study. Clin Transl Allergy 2014;4:7
    106. Bergmann KC, Demoly P, Worm M et al. Efficacy and safety of sublingual tablets of house dust mite allergen extracts in adults with allergic rhinitis. J Allergy Clin Immunol 2014;133:1608鈥?4.e6
    107. Bufe A, Eberle P, Franke-Beckmann E et al. Safety and efficacy in children of an SQ-standardized grass allergen tablet for sublingual immunotherapy. J Allergy Clin Immunol 2009;123:167鈥?3.e7
    108. Wahn U, Tabar A, Kuna P et al. Efficacy and safety of 5-grass-pollen sublingual immunotherapy tablets in pediatric allergic rhinoconjunctivitis. J Allergy Clin Immunol 2009;123:160鈥?.e3
    109. Wahn U, Klimek L, Ploszczuk A et al. High-dose sublingual immunotherapy with single-dose aqueous grass pollen extract in children is effective and safe: a double-blind, placebo-controlled study. J Allergy Clin Immunol 2012;130:886鈥?3.e5
    110. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2010;(12):CD002893
    111. Wilson DR, Torres LI, Durham SR. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev 2003;(2):CD002893
    112. Khinchi MS, Poulsen LK, Carat F, Andre C, Hansen AB, Malling HJ. Clinical efficacy of sublingual and subcutaneous birch pollen allergen-specific immunotherapy: a randomized, placebo-controlled, double-blind, double-dummy study. Allergy 2004;59:45鈥?3
    113. Devillier P, Dreyfus JF, Demoly P, Calderon MA. A meta-analysis of sublingual allergen immunotherapy and pharmacotherapy in pollen-induced seasonal allergic rhinoconjunctivitis. BMC medicine 2014;12:71
    114. Bousquet J, Scheinmann P, Guinnepain MT et al. Sublingual-swallow immunotherapy (SLIT) in patients with asthma due to house-dust mites: a double-blind, placebo-controlled study. Allergy 1999;54:249鈥?0
    115. Pajno GB, Morabito L, Barberio G, and Parmiani S. Clinical and immunologic effects of long-term sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, placebo-controlled study. Allergy 2000;55:842鈥?
    116. Hirsch T, Sahn M, Leupold W. Double-blind placebo-controlled study of sublingual immunotherapy with house dust mite extract (D.pt.) in children. Pediatr Allergy Immunol 1997;8:21鈥?
    117. Bahceciler NN, Isik U, Barlan IB, Basaran MM. Efficacy of sublingual immunotherapy in children with asthma and rhinitis: a double-blind, placebo-controlled study. Pediatr Pulmonol 2001;32:49鈥?5
    118. Mosbech H, Deckelmann R, Blay F de et al. Standardized quality (SQ) house dust mite sublingual immunotherapy tablet (ALK) reduces inhaled corticosteroid use while maintaining asthma control: a randomized, double-blind, placebo-controlled trial. J Allergy Clin Immunol 2014;134:568鈥?5.e7
    119. Nelson HS, Nolte H, Creticos P, Maloney J, Wu J, Bernstein DI. Efficacy and safety of timothy grass allergy immunotherapy tablet treatment in North American adults. J Allergy Clin Immunol 2011;127:72鈥?0.e1-2
    120. Canonica GW, Cox L, Pawankar R et al. Sublingual immunotherapy: World Allergy Organization position paper 2013 update. The World Allergy Organization journal 2014;7:6
    121. Pajno GB, Caminiti L, Crisafulli G et al. Direct comparison between continuous and coseasonal regimen for sublingual immunotherapy in children with grass allergy: a randomized controlled study. Pediatr Allergy Immunol 2011;22:803鈥?
    122. Blaiss M, Maloney J, Nolte H, Gawchik S, Yao R, Skoner DP. Efficacy and safety of timothy grass allergy immunotherapy tablets in North American children and adolescents. J Allergy Clin Immunol 2011;127:64鈥?1.e1-4
    123. Didier A, Malling HJ, Worm M et al. Post-treatment efficacy of discontinuous treatment with 300IR 5-grass pollen sublingual tablet in adults with grass pollen-induced allergic rhinoconjunctivitis. Clin Exp Allergy 2013;43:568鈥?7
    124. Durham SR, Emminger W, Kapp A et al. Long-term clinical efficacy in grass pollen-induced rhinoconjunctivitis after treatment with SQ-standardized grass allergy immunotherapy tablet. J Allergy Clin Immunol 2010;125:131鈥?.e1-7
    125. Durham SR, Emminger W, Kapp A et al. SQ-standardized sublingual grass immunotherapy: confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol 2012;129:717鈥?5.e5
    126. Ott H, Sieber J, Brehler R et al. Efficacy of grass pollen sublingual immunotherapy for three consecutive seasons and after cessation of treatment: the ECRIT study. Allergy 2009;64:179鈥?6
    127. Pfaar O, Klimek L. Efficacy and safety of specific immunotherapy with a high-dose sublingual grass pollen preparation: a double-blind, placebo-controlled trial. Ann Allergy Asthma Immunol 2008;100:256鈥?3
    128. Drachenberg K, Pfeiffer P, Urban E. [Sublingual immunotherapy - results from a multi-centre, randomised, double-blind, placebocontrolled study with a standardised birch and grass/rye pollen extract]. Allergologie 2001;24:525鈥?4
    129. Horak F, St眉bner P, Berger UE, Marks B, Toth J, J盲ger S. Immunotherapy with sublingual birch pollen extract. A short-term double-blind placebo study. J Investig Allergol Clin Immunol 1998;8:165鈥?1
    130. Tonnel AB, Scherpereel A, Douay B et al. Allergic rhinitis due to house dust mites: evaluation of the efficacy of specific sublingual immunotherapy. Allergy 2004;59:491鈥?
    131. Passalacqua G, Albano M, Fregonese L et al. Randomised controlled trial of local allergoid immunotherapy on allergic inflammation in mite-induced rhinocon-junctivitis. Lancet 1998;351:629鈥?2
    132. Lue KH, Lin YH, Sun HL, Lu KH, Hsieh JC, Chou MC. Clinical and immunologic effects of sublingual immunotherapy in asthmatic children sensitized to mites: a double-blind, randomized, placebo-controlled study. Pediatr Allergy Immunol 2006;17:408鈥?5
    133. Niu CK, Chen WY, Huang JL, Lue KH, Wang JY. Efficacy of sublingual immunotherapy with high-dose mite extracts in asthma: a multi-center, double-blind, randomized, and placebo-controlled study in Taiwan. Respir Med 2006;100:1374鈥?3?
    134. Passalacqua G, Pasquali M, Ariano R et al. Randomized double-blind controlled study with sublingual carbamylated allergoid immunotherapy in mild rhinitis due to mites. Allergy 2006;61:849鈥?4
    135. Guez S, Vatrinet C, Fadel R, Andre C. House-dust-mite sublingual-swallow immunotherapy (SLIT) in perennial rhinitis: a double-blind, placebo-controlled study. Allergy 2000;55:369鈥?5
    136. M枚ller C, Dreborg S, Ferdousi HA et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT-study). J Allergy Clin Immunol 2002;109:251鈥?
    137. Niggemann B, Jacobsen L, Dreborg S et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 2006;61:855鈥?
    138. Eng PA, Reinhold M, Gnehm HP. Long-term efficacy of preseasonal grass pollen immunotherapy in children. Allergy 2002;57:306鈥?2
    139. Eng PA, Borer-Reinhold M, Heijnen IA, Gnehm HP. Twelve-year follow-up after discontinuation of preseasonal grass pollen immunotherapy in childhood. Allergy 2006;61:198鈥?01
    140. Purello-D鈥橝mbrosio F, Gangemi S, Merendino RA et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin Exp Allergy 2001;31:1295鈥?02
    141. Pajno GB, Barberio G, De Luca F, Morabito L, and Parmiani S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin Exp Allergy 2001;31:1392鈥?
    142. Di Rienzo V, Marcucci F, Puccinelli P et al. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy 2003;33:206鈥?0
    143. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol 2010;126:969鈥?5
    144. Novembre E, Galli E, Landi F et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J Allergy Clin Immunol 2004;114:851鈥?
    145. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Randomized controlled open study of sublingual immunotherapy for respiratory allergy in real-life: clinical efficacy and more. Allergy 2004;59:1205鈥?0
    146. Valovirta E, Berstad AK, Blic J de et al. Design and recruitment for the GAP trial, investigating the preventive effect on asthma development of an SQ-standardized grass allergy immunotherapy tablet in children with grass pollen-induced allergic rhinoconjunctivitis. Clin Ther 2011;33:1537鈥?6
    147. Schmid-Grendelmeier P. [Recombinant allergens. For routine use or still only science?]. Hautarzt 2010;61:946鈥?3
    148. G枚tzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. Allergy 2008;63:646鈥?9
    149. Kopp MV, Niggemann B, Forster J. House dust mite allergy: complete removal of the provoking allergen is a primary therapeutic approach. Allergy 2009;64:1402鈥?
    150. Muche-Borowski C, Kopp M, Reese I et al. [Evidence-based and consented guideline on allergy prevention - update 2009]. Allergo J 2009;18:332鈥?1
    151. Pfaar O, Biedermann T, Klimek L, Sager A, Robinson DS. Depigmented-polymerized mixed grass/birch pollen extract immunotherapy is effective in polysensitized patients. Allergy 2013;68:1306鈥?3
    152. Nelson HS. Specific immunotherapy with allergen mixes: what is the evidence? Curr Opin Allergy Clin Immunol 2009;9:549鈥?3
    153. Bundes盲rztekammer (B脛K), Kassen盲rztliche Bundesvereinigung (KBV), Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften (AWMF), eds. Nationale Versorgungs Leitlinie Asthma - Langfassung, 2. Aufl. Version 5, 2009, zuletzt ge盲ndert: August 2013. www.leitlinien.de/nvl/asthma/mdb/downloads/nvl/asthma/asthma-2aufl-vers5-lang.pdf
    154. Zuberbier T, Bachert C, Bousquet PJ et al. GA(2) LEN/EAACI pocket guide for allergen-specific immunotherapy for allergic rhinitis and asthma. Allergy 2010;65:1525鈥?0
    155. Demoly P, Piette V, Daures JP. Treatment of allergic rhinitis during pregnancy. Drugs 2003;63:1813鈥?0
    156. Wedi B, Rueff F. [Pharmacoprophylaxis and comedications in allergen-specific immunotherapy]. Hautarzt 2011; 62:663鈥?0
    157. Fodeman J, Jariwala S, Hudes G, Jerschow E, Rosenstreich D. Subcutaneous allergen immunotherapy in 3 patients with HIV. Ann Allergy Asthma Immunol 2010;105:320鈥?
    158. Randhawa IS, Junaid I, Klaustermeyer WB. Allergen immunotherapy in a patient with human immunodeficiency virus: effect on T-cell activation and viral replication. Ann Allergy Asthma Immunol 2007;98:495鈥?
    159. W枚hrl S, Kinaciyan T, Jalili A, Stingl G, Moritz KB. Malignancy and specific allergen immunotherapy: the results of a case series. Int Arch Allergy Immunol 2011;156:313鈥?
    160. M眉ller UR, Haeberli G. Use of beta-blockers during immunotherapy for Hymenoptera venom allergy. J Allergy Clin Immunol 2005;115:606鈥?0
    161. Linneberg A, Madsen F, Skaaby T. Allergen-specific immunotherapy and risk of autoimmune disease. Curr Opin Allergy Clin Immunol 2012;12:635鈥?
    162. Linneberg A, Jacobsen RK, Jespersen L, Abildstrom SZ. Association of subcutaneous allergen-specific immunotherapy with incidence of autoimmune disease, ischemic heart disease, and mortality. J Allergy Clin Immunol 2012;129:413鈥?
    163. Arzneimittelkommission der deutschen 脛rzteschaft (Akd脛), ed. Stellungnahme der Akd脛 zur allergenspezifischen Immuntherapie. Dtsch 脛rztebl 2007;104: A3355-7
    164. Zylka-Menhorn V. Hyposensibilisierung bald nur noch durch 鈥渆rfahrene 脛rzte鈥? Dtsch 脛rztebl 1995;92:A鈥?434
    165. Alvarez-Cuesta E, Bousquet J, Canonica GW, Durham SR, Malling HJ, Valovirta E. Standards for practical allergen-specific immunotherapy. Allergy 2006;61 Suppl 82:1鈥?0
    166. Klimek L. Umsetzung der EU-Richtlinie 2010/32/EU fordert verletzungssichere Spritzen: im HNO-Bereich ist hiervon insbesondere auch die subkutane Immun-therapie (SCIT) betroffen. HNO-Mitteilungen 2013;63:189
    167. Fischer PJ, Friedrichs F. [Practical parameters of hyposensitization]. Monatsschr Kinderheilkd 2013;161:608鈥?5
    168. Calabria CW. Accelerated immunotherapy schedules. Curr Allergy Asthma Rep 2013;13:389鈥?8
    169. Calabria CW, Cox L. Accelerated immunotherapy schedules and premedication. Immunol Allergy Clin North Am 2011;31:251鈥?3, ix
    170. Pfaar O, Wolf H, Klimek L, Schnitker J, W眉stenberg E. Immunologic effect and tolerability of intra-seasonal subcutaneous immunotherapy with an 8-day up-dosing schedule to 10,000 standardized quality-units: a double-blind, randomized, placebo-controlled trial. Clin Ther 2012;34:2072鈥?1
    171. Canonica GW, Bousquet J, Casale T et al. Sublingual immunotherapy: World Allergy Organization Position Paper 2009. Allergy 2009;64 Suppl 91:1鈥?9
    172. Haynes R. Einleitung. In: Haynes RB, Taylor DW, Sackett DL. Compliance Handbuch. M眉nchen: Oldenbourg; 1986. p. 11鈥?
    173. Sondermann N, Shah-Hosseini K, Henkel K, Schwalfenberg A, M枚sges R. [Factors of success for adherence in hyposensitization]. Allergologie 2011;34:441鈥?
    174. Osterberg L, Blaschke T. Adherence to medication. N Engl J Med 2005;353:487鈥?7
    175. Baiardini I, Braido F, Bonini M, Compalati E, Canonica GW. Why do doctors and patients not follow guidelines? Curr Opin Allergy Clin Immunol 2009;9:228鈥?3
    176. Bousquet J, Khaltaev N, Cruz AA et al. Allergic rhinitis and its impact on asthma (ARIA) 2008 update (in collaboration with the World Health Organization, GA(2)LEN and AllerGen). Allergy 2008;63 Suppl 86:8鈥?60
    177. Senna G, Ridolo E, Calderon M, Lombardi C, Canonica GW, Passalacqua G. Evidence of adherence to allergen-specific immunotherapy. Curr Opin Allergy Clin Immunol 2009;9:544鈥?
    178. Claes C, Mittendorf T, Graf von der Schulenburg JM. Persistence and frequency of prescriptions of subcutaneous allergen-specific immunotherapy (SCIT) prescribed within the German statutory health insurance. Med Klin (Munich) 2009;104:536鈥?2
    179. Aschemann U, Schulte P, Hecker H. Untersuchung zur Compliance eines anwenderfreundlichen Allergoids. Allergo J 2010;19(S1):63 (abstract)
    180. Egert-Schmidt A, Martin E, M眉ller U, Schulte M, Thum-Oltmer S. Patienten-Compliance in der Spezifischen Immuntherapie - Ein Vergleich von SCIT- und SLIT-Pr盲paraten. Allergo J 2011;20(S1):S40 (abstract)
    181. Senna G, Lombardi C, Canonica GW, Passalacqua G. How adherent to sublingual immunotherapy prescriptions are patients? The manufacturers鈥?viewpoint. J Allergy Clin Immunol 2010;126:668鈥?
    182. Sieber J, De Geest S, Shah-Hosseini K, M枚sges R. Medication persistence with long-term, specific grass pollen immunotherapy measured by prescription renewal rates. Curr Med Res Opin 2011;27:855鈥?1
    183. Eberle P, Schreder H, Shah-Hosseini K, M枚sges R. [Medication persistence in children and young people on long-term, grass pollenspecific immunotherapy - measured by prescription renewal rates]. Allergologie 2013;36:9鈥?8
    184. Przybilla B, Rueff F, Walker A et al. [Diagnosis and therapy of bee and wasp venom allergy]. Allergo J 2011;20:318鈥?9
    185. Cox L, Calderon M, Pfaar O. Subcutaneous allergen immunotherapy for allergic disease: examining efficacy, safety and cost-effectiveness of current and novel formulations. Immunotherapy 2012;4:601鈥?6
    186. Malling HJ. Minimising the risks of allergen-specific injection immunotherapy. Drug Saf 2000;23:323鈥?2
    187. Kelso JM. The rate of systemic reactions to immunotherapy injections is the same whether or not the dose is reduced after a local reaction. Ann Allergy Asthma Immunol 2004;92:225鈥?
    188. Vogelbruch M, Nuss B, K枚rner M, Kapp A, Kiehl P, Bohm W. Aluminium-induced granulomas after inaccurate intradermal hyposensitization injections of aluminium-adsorbed depot preparations. Allergy 2000;55:883鈥?
    189. Netterlid E, Hinds茅n M, Bj枚rk J et al. There is an association between contact allergy to aluminium and persistent subcutaneous nodules in children undergoing hyposensitization therapy. Contact Dermatitis 2009;60:41鈥?
    190. Frost L, Johansen P, Pedersen S, Veien N, Ostergaard PA, Nielsen MH. Persistent subcutaneous nodules in children hyposensitized with aluminium-containing allergen extracts. Allergy 1985;40:368鈥?2
    191. Lopez S, Pelaez A, Navarro LA, Montesinos E, Morales C, Carda C. Aluminium allergy in patients hyposensitized with aluminium-precipitated antigen extracts. Contact Dermatitis 1994;31:37鈥?0
    192. Ragusa FV, Passalacqua G, Gambardella R et al. Nonfatal systemic reactions to subcutaneous immunotherapy: a 10-year experience. J Investig Allergol Clin Immunol 1997;7:151鈥?
    193. Burks AW, Calderon MA, Casale T et al. Update on allergy immunotherapy: American Academy of Allergy, Asthma & Immunology/European Academy of Allergy and Clinical Immunology/PRACTALL consensus report. J Allergy Clin Immunol 2013;131:1288鈥?6.e3
    194. Epstein TG, Liss GM, Murphy-Berendts K, Bernstein DI. AAAAI and ACAAI surveillance study of subcutaneous immunotherapy, year 3: what practices modify the risk of systemic reactions? Ann Allergy Asthma Immunol 2013;110:274鈥?, 278.e1
    195. Bernstein DI, Wanner M, Borish L, Liss GM, Immunotherapy Committee AAoAA, and Immunology: Twelve-year survey of fatal reactions to allergen injections and skin testing: 1990-2001. J Allergy Clin Immunol 2004; 113, 1129鈥?6.
    196. L眉deritz-P眉chel U, Keller-Stanislawski B, Haustein D. [Risk reevaluation of diagnostic and therapeutic allergen extracts. An analysis of adverse drug reactions from 1991 to 2000]. Bundesgesundheitsbl Gesundheitsforsch Gesundheitsschutz 2001;44:709鈥?8
    197. Makatsori M, Calderon MA. Anaphylaxis: still a ghost behind allergen immunotherapy. Curr Opin Allergy Clin Immunol 2014; 14(4): 316鈥?2
    198. Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G. Speaking the same language: The World Allergy Organization subcutaneous immunotherapy systemic reaction grading system. J Allergy Clin Immunol 2010;125:569鈥?4,574.e1-574.e7
    199. Nielsen L, Johnsen CR, Mosbech H, Poulsen LK, Malling HJ. Antihistamine premedication in specific cluster immunotherapy: a double-blind, placebo-controlled study. J Allergy Clin Immunol 1996;97:1207鈥?3
    200. Reimers A, Hari Y, M眉ller U. Reduction of side-effects from ultrarush immunotherapy with honeybee venom by pretreatment with fexofenadine: a double-blind, placebo-controlled trial. Allergy 2000;55:484鈥?
    201. Cox LS, Larenas Linnemann D, Nolte H, Weldon D, Finegold I, Nelson HS. Sublingual immunotherapy: a comprehensive review. J Allergy Clin Immunol 2006;117:1021鈥?5
    202. Calderon MA, Simons FE, Malling HJ, Lockey RF, Moingeon P, Demoly P. Sublingual allergen immunotherapy: mode of action and its relationship with the safety profile. Allergy 2012;67:302鈥?1
    203. Passalacqua G, Garelli V, Sclifo F, Canonica GW. Sublingual immunotherapy for allergic rhinitis and conjunctivitis. Immunotherapy 2013;5:257鈥?4
    204. Groot H de, Bijl A. Anaphylactic reaction after the first dose of sublingual immunotherapy with grass pollen tablet. Allergy 2009;64:963鈥?
    205. Passalacqua G, Baena-Cagnani CE, Bousquet J et al. Grading local side effects of sublingual immunotherapy for respiratory allergy: speaking the same language. J Allergy Clin Immunol 2013;132:93鈥?
    206. Swissmedic, ed. Neues Heilmittelgesetz: Meldepflicht der Fachleute f眉r unerw眉nschte Arzneitmittelwirkungen. Schweiz 脛rztezeitung 2002;83:819-22
    207. Ring J, Beyer K, Biedermann T et al. Guideline for acute therapy and management of anaphylaxis. S2 Guideline of the German Society for Allergology and Clinical Immunology (DGAKI), the Association of German Allergologists (AeDA), the Society of Pediatric Allergy and Environmental Medicine (GPA), the German Academy of Allergology and Environmental Medicine (DAAU), the German Professional Association of Pediatricians (BVKJ), the Austrian Society for Allergology and Immunology (脰GAI), the Swiss Society for Allergy and Immunology (SGAI), the German Society of Anaesthesiology and Intensive Care Medicine (DGAI), the German Society of Pharmacology (DGP), the German Society for Psychosomatic Medicine (DGPM), the German Working Group of Anaphylaxis Training and Education (AGATE) and the patient organization German Allergy and Asthma Association (DAAB) Allergo J Int 2014;23:96鈥?12
    208. Simons FE, Ardusso LR, Bilo MB et al. 2012 Update: World Allergy Organization Guidelines for the assessment and management of anaphylaxis. Curr Opin Allergy Clin Immunol 2012;12:389鈥?9
    209. Dhami S, Panesar SS, Rader T et al. The acute and long-term management of anaphylaxis: protocol for a systematic review. Clin Transl Allergy 2013;3:14
    210. Reeve L, Baldrick P, Hewings S, Skinner M. A battery of genotoxicity studies with an allergy vaccine adjuvanted with monophosphoryl lipid A (MPL(R)) for the treatment of grass pollen allergy. J Appl Toxicol 2012;32: 608鈥?6
    211. Pfaar O, Cazan D, Klimek L, Larenas-Linnemann D, Calderon MA. Adjuvants for immunotherapy. Curr Opin Allergy Clin Immunol 2012;12:648鈥?7
    212. Jutel M, Solarewicz-Madejek K, Smolinska S. Recombinant allergens: The present and the future. Hum Vaccin Immunother 2012;8:1534鈥?3
    213. Patel D, Couroux P, Hickey P et al. Fel d 1-derived peptide antigen desensitization shows a persistent treatment effect 1 year after the start of dosing: a randomized, placebo-controlled study. J Allergy Clin Immunol 2013; 131:103鈥?.e1-7
    214. Johansen P, Moos S von, Mohanan D, K眉ndig TM, Senti G. New routes for allergen immunotherapy. Hum Vaccin Immunother 2012;8:1525鈥?3
    215. Senti G, Prinz Vavricka BM, Erdmann I et al. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A 2008;105:17908鈥?2
    216. Senti G, Moos S von, Tay F et al. Epicutaneous allergen-specific immunotherapy ameliorates grass pollen-induced rhinoconjunctivitis: A double-blind, placebo-controlled dose escalation study. J Allergy Clin Immunol 2012;129:128鈥?5
    217. Senti G, Crameri R, Kuster D et al. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol 2012;129: 1290鈥?
    218. Kopp MV. Role of immunmodulators in allergen-specific immunotherapy. Allergy 2011;66:792鈥?
    219. Larenas-Linnemann D, Wahn U, Kopp M. Use of omalizumab to improve desensitization safety in allergen immunotherapy. J Allergy Clin Immunol 2014;133:937.e2
    220. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:1572鈥?
    221. Bousquet J, Sch眉nemann HJ, Samolinski B et al. Allergic Rhinitis and its Impact on Asthma (ARIA): achievements in 10 years and future needs. J Allergy Clin Immunol 2012;130:1049鈥?2
  • 刊物主题：General Practice / Family Medicine;
  • 出版者：Urban & Vogel
  • ISSN：2195-6405
文摘

© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号

地址：北京市海淀区学院路29号 邮编：100083

电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700